Top Markets
#1 EXOD EXOD +56.80%
#2 MowCat MowCat +48.06%
#3 CoW Protocol CoW Protocol +37.63%
#4 Glidr Glidr +36.87%
#5 Humanity Humanity +28.04%
#6 Walrus Walrus +22.05%
#7 Codatta Codatta +21.20%
#8 Enso Enso +19.64%
#9 The Black Bull The Black Bull +17.55%
#10 Tutorial Tutorial +14.31%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
ReShape Lifesciences Inc. ReShape Lifesciences Inc.

ReShape Lifesciences Inc.

RSLS
Rank in Stocks #36770
Founded in 2002 and based in San Clemente, California, ReShape Lifesciences... Founded in 2002 and based in San Clemente, California, ReShape Lifesciences Inc. operates as a medical device company dedicated to addressing obesity and metabolic diseases. The company's market extends throughout the United States, Australia, Europe, and globally. Its diverse product lineup features the Lap-Band System, a minimally invasive, long-term solution for severe obesity that offers an alternative to more extensive surgical interventions like gastric bypass or sleeve gastrectomy. Under development is the ReShape Vest system, an investigational, minimally invasive device that is laparoscopically implanted around the stomach to assist obese and morbidly obese patients in losing weight, without cutting or permanently removing parts of the stomach or bypassing any section of the gastrointestinal tract. ReShape also supports patients through the ReShapeCare virtual health coaching program, a telehealth service aimed at promoting healthy lifestyle adjustments for individuals undergoing medically supervised weight management. Additionally, the company is conducting preclinical development for ReShape Diabetes Bloc-Stim Neuromodulation, a technology intended for the treatment of type 2 diabetes mellitus. Among its offerings is the Obalon Balloon System, a swallowable capsule used to monitor and display the balloon's exact position during its placement. The company, initially incorporated as EnteroMedics Inc., changed its name to ReShape Lifesciences Inc. in 2017.
Share Price
$3.92
Last synced: 2025-08-14
Market Cap
$2.34M
Change (1 day)
-69.38%
Change (1 year)
0.00%
Country
US
Trade ReShape Lifesciences Inc. (RSLS)

Category

Healthcare
P/E ratio for ReShape Lifesciences Inc. (RSLS)
P/E ratio as of 2026 TTM: 0
According to ReShape Lifesciences Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for ReShape Lifesciences Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
 35.77 -
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
 34.86 -
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
 21.39 -
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
 20.90 -
US
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
Edwards Lifesciences Corporation
EW.US
 52.64 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.